Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group

Journal of the National Cancer Institute
D C TormeyH C Falkson

Abstract

Data from a pilot study published in 1984 suggested that tamoxifen administration (as adjuvant hormonal therapy) for more than 5 years after initial breast cancer surgery might have therapeutic benefit. A randomized trial was performed to assess the efficacy of maintaining tamoxifen therapy beyond 5 years in women with axillary lymph node-positive breast cancer who had been treated with surgery followed by 1 year of chemotherapy and 5 years of tamoxifen. One hundred ninety-four women (87 postmenopausal and 107 premenopasual) enrolled in two concurrent Eastern Cooperative Oncology Group adjuvant trials (E4181 for postmenopausal patients and E5181 for premenopausal patients) were randomly assigned to continued tamoxifen therapy or observation. Data for 193 women (87 postmenopausal and 106 premenopausal) were available for analysis. Median follow-up is 5.6 years since the randomization at 5 years, with the longest follow-up being 8.0 years. The major analyses measured events from the time of randomization until relapse or death; these included time-to-relapse analyses, with new opposite-breast cancers counted as treatment failures, and survival analyses. Time-to-relapse comparisons and survival comparisons for women in the two tre...Continue Reading

Citations

Sep 9, 1999·Journal of Surgical Oncology·A S Heerdt, P I Borgen
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·M Noguchi, K Miwa
Jan 16, 2002·Breast Cancer : the Journal of the Japanese Breast Cancer Society·J S Abrams
Jul 19, 2013·Breast Cancer Research and Treatment·Fausto PetrelliSandro Barni
Jun 12, 2002·Current Treatment Options in Oncology·A C Wolff, N E Davidson
Jun 12, 2002·Current Treatment Options in Oncology·M Cianfrocca, L J Goldstein
Mar 3, 2004·Current Treatment Options in Oncology·Martine Extermann
Dec 22, 2004·Current Oncology Reports·Lisa E Sokolowicz, William J Gradishar
Jul 26, 2008·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Shigehira Saji, Katsumasa Kuroi
Sep 23, 2011·Advances in Therapy·A Fernández OrtegaJ Cortés Castán
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Kathrin Strasser-WeipplPaul E Goss
Oct 5, 2002·Cancer Treatment Reviews·M ClemonsA Howell
Oct 2, 1998·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·G Mathé
Mar 13, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C Lohrisch, M J Piccart
Nov 5, 2010·Nature Reviews. Cancer·Paul E Goss, Ann F Chambers
Jul 25, 2013·Nature Reviews. Clinical Oncology·Michail Ignatiadis, Christos Sotiriou
Jul 15, 1998·British Journal of Clinical Pharmacology·C R Meier, H Jick
Nov 26, 1998·The New England Journal of Medicine·C K Osborne
Oct 11, 2003·The New England Journal of Medicine·Harold J Burstein
May 28, 2002·Cancer Biotherapy & Radiopharmaceuticals·Helen K Chew
May 3, 2001·Journal of the National Cancer Institute·J S Abrams
Feb 21, 2002·Journal of the National Cancer Institute·Ruth M O'ReganV Craig Jordan
Dec 13, 2007·Journal of the National Cancer Institute·Raimund JakeszUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Aug 13, 2008·Journal of the National Cancer Institute·Abenaa M BrewsterFrancisco J Esteva
Oct 9, 2008·Current Opinion in Oncology·Natasa SnojTanja Cufer
Jul 11, 2007·The Cancer Journal·Tessa Cigler, Paul E Goss
Jun 6, 1998·BMJ : British Medical Journal·D ReaR Gray
Nov 30, 1998·BMJ : British Medical Journal·D A Cameron
Nov 6, 2009·Breast Cancer Research : BCR·Georgios KesisisDavid Miles
Mar 4, 2014·PloS One·Mustafa Al-MubarakEitan Amir
Apr 30, 2013·Endocrine-related Cancer·Per Eystein Lønning, Hans Petter Eikesdal
Jan 16, 2002·Drugs·Sally Clive, J Michael Dixon
Mar 22, 2002·The Lancet Oncology·V C Jordan
Jul 18, 2014·Breast Cancer Research : BCR·Gaia Schiavon, Ian E Smith
Jun 28, 2011·Journal of Cell Communication and Signaling·Shreya BanerjeeSushanta K Banerjee
Apr 14, 2010·Expert Opinion on Investigational Drugs·Per Eystein Lønning
Oct 29, 2008·Current Medical Research and Opinion·N Harbeck
Oct 2, 2001·Cancer Investigation·L F Hutchins, C L Arick
Nov 3, 2012·Critical Reviews in Oncology/hematology·Michaela J HigginsPaul E Goss
Jan 22, 2008·Current Problems in Surgery·Judy C BougheyKelly K Hunt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.